التفاصيل البيبلوغرافية
| العنوان: |
Why Lilly's Obesity Treatment Update Sent Novo, Madrigal And Viking Shares Diving. |
| المؤلفون: |
GATLIN, ALLISON (AUTHOR) |
| المصدر: |
Investors Business Daily. 6/27/2023, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*STOCK prices, OBESITY, GLUCAGON-like peptide-1 receptor, DIVERS, WEIGHT loss |
| الشركة/الكيان: |
NOVO Nordisk A/S NVO |
| مستخلص: |
B Eli Lilly b (LLY) stock surged closer to a record high Tuesday after the company set a new bar among weight-loss drugs. Patients without diabetes who were diagnosed with obesity or being overweight lost an average 24.2% of their body weight after taking Lilly's next-generation anti-obesity drug, retatrutide, over 48 weeks, the company said late Monday. [Extracted from the article] |
|
Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
